Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 8/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MTTP | P55157 | 2/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3998698 | 0.94 | KCNQ3 (0.42) | KCNQ3KCNQ2PTGDR2PTPN11PPARD | |
| SCHEMBL5927367 | 0.94 | CYP26A1 (0.42) | KCNQ3KCNQ2PTGDR2PTPN11ALDH1A1 | |
| SCHEMBL3995234 | 0.93 | MMP12 (0.48) | KCNQ3KCNQ2PTGDR2PTPN11ALDH1A1 | |
| SCHEMBL3995217 | 0.93 | PTPN11 (0.46) | PTPN11CTSAALDH1A1LMNAMAPK1 | |
| SCHEMBL3991621 | 0.91 | PTPN11 (0.44) | PTPN11CTSAALDH1A1LMNAMAPK1 | |
| SCHEMBL5926898 | 0.91 | FFAR4 (0.46) | KCNQ3KCNQ2PTPN11CTSAALDH1A1 | |
| SCHEMBL5926613 | 0.91 | KCNQ3 (0.50) | KCNQ3KCNQ2CTSAALDH1A1LMNA | |
| SCHEMBL4831640 | 0.87 | KIFC1 (0.48) | KCNQ3KCNQ2PTGDR2PTPN11PPARD | |
| SCHEMBL3999740 | 0.87 | KIFC1 (0.48) | KCNQ3KCNQ2PTGDR2PTPN11PPARD | |
| SCHEMBL5927443 | 0.87 | LMNA (0.45) | KCNQ3KCNQ2CTSAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | KCNQ3 666/4885KCNQ2 656/4885PTGDR2 646/4885 |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | KCNQ3 1174/4885KCNQ2 1112/4885PTGDR2 450/4885 |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | KCNQ3 907/4885KCNQ2 1261/4885PTGDR2 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.